All In MedTech

Device Trial Radar · NCT06819865

A Real-World Study of EkoSonic Endovascular System in Chinese Populations With Acute Pulmonary Embolism

EkoSonic Endovascular System in China RWS(ANTEATER)

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Sep 30, 2026

Primary completion

May 30, 2028

Study completion May 30, 2029

Sponsor

Lead sponsor
Boston Scientific CorporationPublic (BSX)
Sponsor type
Industry
First posted
Feb 11, 2025

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years

Summary

As written by the sponsor on the registry.

This study to collect the real-world clinical outcome data of EkoSonicTM Endovascular System in Chinese patients with acute pulmonary embolism during practical clinical care.

Conditions

  • Acute Pulmonary Embolism

Interventions

  • EkoSonicTM Endovascular SystemDevice

    EkoSonicTM Endovascular System and its upgraded versions if applicable The EkoSonicTM Endovascular System is a non-implanted system comprising a sterile, single-use EkoSonic Endovascular Device (Infusion Catheter and Ultrasonic Core) and reusable EKOSTM Control System 4.0(Control Unit, Connector Interface Cable and power cord).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RV vs LV end-diastolic diameter ratioTime frame: after the completion of EKOS treatment 48 hours compared with the baseline

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The first Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.